Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplatation

William R. Vogler, Anita C. Olson, Shinichiro Okamoto, Lewis B. Somberg, Lewis Glasser

Research output: Contribution to journalArticle

21 Citations (Scopus)

Abstract

The selective cytocidal effect of alkyl lysophospholipids against neoplastic cells while sparing normal cells make these ideal candidates for purging leukemic cells from bone marrows obtained during remission. To test the feasibility of such an approach, a murine model and an in vitro human cell model were developed. In the murine system a mixture of normal bone marrow cells and WEHI IIIB myelomonocytic leukemic cells was incubated with varying doses of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-Me) for 24 hr before being injected into tail veins of lethally irradiated Balb/c mice. At doses of 20 and 100 μg/ml, long-term survivors were noted. The additional steps of freezing and thawing following incubation resulted in significantly longer survival with doses of 10 to 50 μg/ml, but were toxic to marrow stem cells at 100 μg/ml. In the in vitro model, normal marrow progenitor cells and leukemic cells (the promyelocytic cell line HL60) were exposed to varying concentrations of ET-Me for 1 and 4 hr alone or mixed, and clonogenicity was assayed by colony formation in semisolid medium during 7-14 days' incubation. At doses up to 100 μg/ml exposed for 4 hr normal progenitor cells were spared and HL60 colonies eliminated. Other phospholipids analogues were less effective in eliminating leukemic cells, but spared normal progenitor cells. A survey of fresh leukemic cells found varying degrees of sensitivity to ET-Me, indicating the need for testing a variety of compounds. These studies clearly indicated the potential usefulness of alkyl lysophospholipid compounds in selectively purging leukemic cells from remission marrows for autologous bone marrow transplantation.

Original languageEnglish
Pages (from-to)919-924
Number of pages6
JournalLipids
Volume22
Issue number11
DOIs
Publication statusPublished - 1987 Nov
Externally publishedYes

Fingerprint

Lysophospholipids
bone marrow
Purging
Bone
Bone Marrow
Cells
stem cells
Thawing
Stem Cells
Poisons
cells
Stem cells
Freezing
Phospholipids
remission
dosage
Bone Marrow Cells
Testing
variety trials
bone marrow transplant

ASJC Scopus subject areas

  • Medicine (miscellaneous)
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Food Science

Cite this

Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplatation. / Vogler, William R.; Olson, Anita C.; Okamoto, Shinichiro; Somberg, Lewis B.; Glasser, Lewis.

In: Lipids, Vol. 22, No. 11, 11.1987, p. 919-924.

Research output: Contribution to journalArticle

Vogler, William R. ; Olson, Anita C. ; Okamoto, Shinichiro ; Somberg, Lewis B. ; Glasser, Lewis. / Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplatation. In: Lipids. 1987 ; Vol. 22, No. 11. pp. 919-924.
@article{d9b83f8a35a9461c95fe96ddddac36c6,
title = "Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplatation",
abstract = "The selective cytocidal effect of alkyl lysophospholipids against neoplastic cells while sparing normal cells make these ideal candidates for purging leukemic cells from bone marrows obtained during remission. To test the feasibility of such an approach, a murine model and an in vitro human cell model were developed. In the murine system a mixture of normal bone marrow cells and WEHI IIIB myelomonocytic leukemic cells was incubated with varying doses of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-Me) for 24 hr before being injected into tail veins of lethally irradiated Balb/c mice. At doses of 20 and 100 μg/ml, long-term survivors were noted. The additional steps of freezing and thawing following incubation resulted in significantly longer survival with doses of 10 to 50 μg/ml, but were toxic to marrow stem cells at 100 μg/ml. In the in vitro model, normal marrow progenitor cells and leukemic cells (the promyelocytic cell line HL60) were exposed to varying concentrations of ET-Me for 1 and 4 hr alone or mixed, and clonogenicity was assayed by colony formation in semisolid medium during 7-14 days' incubation. At doses up to 100 μg/ml exposed for 4 hr normal progenitor cells were spared and HL60 colonies eliminated. Other phospholipids analogues were less effective in eliminating leukemic cells, but spared normal progenitor cells. A survey of fresh leukemic cells found varying degrees of sensitivity to ET-Me, indicating the need for testing a variety of compounds. These studies clearly indicated the potential usefulness of alkyl lysophospholipid compounds in selectively purging leukemic cells from remission marrows for autologous bone marrow transplantation.",
author = "Vogler, {William R.} and Olson, {Anita C.} and Shinichiro Okamoto and Somberg, {Lewis B.} and Lewis Glasser",
year = "1987",
month = "11",
doi = "10.1007/BF02535555",
language = "English",
volume = "22",
pages = "919--924",
journal = "Lipids",
issn = "0024-4201",
publisher = "Springer Verlag",
number = "11",

}

TY - JOUR

T1 - Experimental studies on the role of alkyl lysophospholipids in autologous bone marrow transplatation

AU - Vogler, William R.

AU - Olson, Anita C.

AU - Okamoto, Shinichiro

AU - Somberg, Lewis B.

AU - Glasser, Lewis

PY - 1987/11

Y1 - 1987/11

N2 - The selective cytocidal effect of alkyl lysophospholipids against neoplastic cells while sparing normal cells make these ideal candidates for purging leukemic cells from bone marrows obtained during remission. To test the feasibility of such an approach, a murine model and an in vitro human cell model were developed. In the murine system a mixture of normal bone marrow cells and WEHI IIIB myelomonocytic leukemic cells was incubated with varying doses of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-Me) for 24 hr before being injected into tail veins of lethally irradiated Balb/c mice. At doses of 20 and 100 μg/ml, long-term survivors were noted. The additional steps of freezing and thawing following incubation resulted in significantly longer survival with doses of 10 to 50 μg/ml, but were toxic to marrow stem cells at 100 μg/ml. In the in vitro model, normal marrow progenitor cells and leukemic cells (the promyelocytic cell line HL60) were exposed to varying concentrations of ET-Me for 1 and 4 hr alone or mixed, and clonogenicity was assayed by colony formation in semisolid medium during 7-14 days' incubation. At doses up to 100 μg/ml exposed for 4 hr normal progenitor cells were spared and HL60 colonies eliminated. Other phospholipids analogues were less effective in eliminating leukemic cells, but spared normal progenitor cells. A survey of fresh leukemic cells found varying degrees of sensitivity to ET-Me, indicating the need for testing a variety of compounds. These studies clearly indicated the potential usefulness of alkyl lysophospholipid compounds in selectively purging leukemic cells from remission marrows for autologous bone marrow transplantation.

AB - The selective cytocidal effect of alkyl lysophospholipids against neoplastic cells while sparing normal cells make these ideal candidates for purging leukemic cells from bone marrows obtained during remission. To test the feasibility of such an approach, a murine model and an in vitro human cell model were developed. In the murine system a mixture of normal bone marrow cells and WEHI IIIB myelomonocytic leukemic cells was incubated with varying doses of 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine (ET-Me) for 24 hr before being injected into tail veins of lethally irradiated Balb/c mice. At doses of 20 and 100 μg/ml, long-term survivors were noted. The additional steps of freezing and thawing following incubation resulted in significantly longer survival with doses of 10 to 50 μg/ml, but were toxic to marrow stem cells at 100 μg/ml. In the in vitro model, normal marrow progenitor cells and leukemic cells (the promyelocytic cell line HL60) were exposed to varying concentrations of ET-Me for 1 and 4 hr alone or mixed, and clonogenicity was assayed by colony formation in semisolid medium during 7-14 days' incubation. At doses up to 100 μg/ml exposed for 4 hr normal progenitor cells were spared and HL60 colonies eliminated. Other phospholipids analogues were less effective in eliminating leukemic cells, but spared normal progenitor cells. A survey of fresh leukemic cells found varying degrees of sensitivity to ET-Me, indicating the need for testing a variety of compounds. These studies clearly indicated the potential usefulness of alkyl lysophospholipid compounds in selectively purging leukemic cells from remission marrows for autologous bone marrow transplantation.

UR - http://www.scopus.com/inward/record.url?scp=0023503111&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023503111&partnerID=8YFLogxK

U2 - 10.1007/BF02535555

DO - 10.1007/BF02535555

M3 - Article

C2 - 3328027

AN - SCOPUS:0023503111

VL - 22

SP - 919

EP - 924

JO - Lipids

JF - Lipids

SN - 0024-4201

IS - 11

ER -